Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.11 is 67% above its 5-year average of -6.31, near the high end of its 5-year range (-11.20–-2.11).
Reported quarterly EPS; no daily interpolation. Q3 FY2026 (2026-06-30): -0.34.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.11
EARNINGS PER SHARE (EPS) AVG TTM
N/A
EARNINGS PER SHARE (EPS) AVG 3Y
-4.90
EARNINGS PER SHARE (EPS) AVG 5Y
-6.31
EARNINGS PER SHARE (EPS) AVG 10Y
-3.90
EARNINGS PER SHARE (EPS) AVG 15Y
-2.86
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+56.94%
CURRENT VS 5Y AVG
+66.55%
CURRENT VS 10Y AVG
+45.94%
CURRENT VS 15Y AVG
+26.31%
CURRENT VS 20Y AVG
N/A
Citius Pharmaceuticals, Inc.
Market Cap
$13.90M
Earnings Per Share (EPS)
-2.11
TTM Avg
N/A
3Y Avg
-4.90
5Y Avg
-6.31
Market Cap
$13.97M
Earnings Per Share (EPS)
-29.90
TTM Avg
-175.25
3Y Avg
-40254.86
5Y Avg
-180507.78
Market Cap
$14.55M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.57M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.17
3Y Avg
-1.46
5Y Avg
-1.36
Market Cap
$13.71M
Earnings Per Share (EPS)
-1.87
TTM Avg
-10.75
3Y Avg
-23.11
5Y Avg
-21.98
Market Cap
$13.45M
Earnings Per Share (EPS)
-11.33
TTM Avg
-17.89
3Y Avg
-30.77
5Y Avg
-41.73
Market Cap
$15.08M
Earnings Per Share (EPS)
-13.07
TTM Avg
-13.67
3Y Avg
-19.10
5Y Avg
-23.67
Market Cap
$13.27M
Earnings Per Share (EPS)
-1.39
TTM Avg
-1.16
3Y Avg
-1.40
5Y Avg
-1.09
Market Cap
$15.25M
Earnings Per Share (EPS)
-2.46
TTM Avg
-7.80
3Y Avg
-9.74
5Y Avg
-7.20
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.90M | -2.11 | N/A | -4.90 | -6.31 |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | -29.90 | -175.25 | -40254.86 | -180507.78 |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.55M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | N/A | -1.17 | -1.46 | -1.36 |
| IN8bio, Inc. (INAB)vs › | $13.71M | -1.87 | -10.75 | -23.11 | -21.98 |
| Passage Bio, Inc. (PASG)vs › | $13.45M | -11.33 | -17.89 | -30.77 | -41.73 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.08M | -13.07 | -13.67 | -19.10 | -23.67 |
| Optimi Health Corp. (OPTH)vs › | $13.27M | -1.39 | -1.16 | -1.40 | -1.09 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.25M | -2.46 | -7.80 | -9.74 | -7.20 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -0.77 | -1.25 | -1.82 | -1.86 |
Trailing EPS (TTM)
$-2.11
Forward EPS (Est.)
$-1.44
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-09-30 | -3.38 |
| 2023-09-30 | -5.57 |
| 2022-09-30 | -5.75 |
| 2021-09-30 | -5.64 |
| 2020-09-30 | -11.20 |
| 2019-09-30 | -0.77 |
| 2018-09-30 | -1.17 |
| 2017-09-30 | -1.89 |
| 2016-09-30 | -2.29 |
| 2015-09-30 | -1.37 |
| 2014-09-30 | -0.95 |
| 2013-09-30 | -0.04 |
| 2012-09-30 | -0.03 |
| 2011-09-30 | -0.04 |
